Hong Kong’s Family Office 2.0 spurs new US$100 million fund to attract global wealth 

Editorial Team - MedTech World
Written by Editorial Team - MedTech World

A new US$100 million fund, launched by five Hong Kong-based family offices, is set to tap into the wave of opportunities created by the government’s Family Office 2.0 plan, an initiative designed to attract more global high-net-worth individuals to invest in the city. 

The fund, named Inspira, is structured as a closed-end investment vehicle focusing on private credit and other stable-income projects. It primarily targets affluent families, particularly those seeking residency in Hong Kong through the Capital Investment Entrant Scheme (CIES), the city’s cash-for-residency programme that encourages foreign investment. 

Strengthening Hong Kong’s position as a global wealth hub 

The launch of Inspira comes at a strategic time. Following the government’s latest policy address, Hong Kong is aiming to attract an additional 220 family offices by 2028, building on the success of its earlier goal of bringing in 200 between 2023 and 2025. This move reinforces the city’s ambition to strengthen its status as a premier hub for global wealth management. 

Initially driven by interest from wealthy mainland Chinese families, Hong Kong’s family office ecosystem is now expanding its reach to investors from Europe, Asia, and the Middle East. The government’s investment promotion agency, InvestHK, has been actively engaging with international families, highlighting Hong Kong’s role as a strategic gateway to Asian markets. 

Interest among European families, in particular, has been growing. Many view Hong Kong as an ideal base for diversifying their portfolios and participating in the region’s economic growth. 

Inspira: Stable income and managed risk for family investors 

The Inspira fund seeks to capitalise on this momentum by offering investment products that provide steady returns with managed risk, a combination increasingly sought after by family offices worldwide. 

At its core, Inspira focuses on private credit, a segment comprising loans made by private investors and backed by collateral. This structure allows investors to achieve higher yields compared to traditional deposits or fixed-income products, while maintaining a conservative risk profile. The fund’s design aligns well with the preferences of wealthy families who prioritise capital preservation and consistent income streams. 

Adding further credibility to the initiative, the founding family offices have invested their own capital into the fund, a move that signals alignment of interest and confidence in its long-term prospects. Inspira has also qualified as an eligible investment under the CIES, offering investors not only financial returns but also a streamlined path to Hong Kong residency. 

A new chapter for global capital flow into Asia 

Since its reintroduction in 2024, the CIES has already drawn significant attention, with over HK$16.5 billion in verified investments as of April. Of this, authorised funds and equities account for nearly two-thirds, underscoring strong demand for professionally managed investment vehicles like Inspira. 

Beyond attracting capital, initiatives such as Inspira reflect Hong Kong’s broader vision to strengthen its financial ecosystem and position itself as a bridge for global wealth flowing into Asia. By combining innovative financial products with progressive residency policies, the city is laying the groundwork for a new era of family office growth and international engagement. 

Looking ahead: MedTech World expands to Hong Kong 

As Hong Kong continues to emerge as a hub for investment and innovation, MedTech World will host its first flagship event in Hong Kong from 16 to 18 September 2026, bringing together global leaders to bridge APAC investment and innovation. But before that, all eyes are on MedTech Malta 2025, happening from 12 to 14 November — just around the corner. 

Book your tickets now and be part of the conversations driving the next wave of healthcare and technology transformation. 

MedTech Malta 2025